Published in Invest Radiol on November 01, 2005
Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol (2008) 2.52
Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. Contrast Media Mol Imaging (2009) 2.48
Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review. J Cereb Blood Flow Metab (2009) 2.43
Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging (2009) 1.95
Acquisition and reconstruction of undersampled radial data for myocardial perfusion magnetic resonance imaging. J Magn Reson Imaging (2009) 1.92
T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson (2012) 1.88
Uncertainty and bias in contrast concentration measurements using spoiled gradient echo pulse sequences. Phys Med Biol (2008) 1.88
T1 mapping of the myocardium: intra-individual assessment of post-contrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson (2012) 1.55
Gd(III)-nanodiamond conjugates for MRI contrast enhancement. Nano Lett (2010) 1.50
Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement: integration of findings from CAD and SLE patients. JACC Cardiovasc Imaging (2014) 1.50
Synthesis of multimeric MR contrast agents for cellular imaging. J Am Chem Soc (2008) 1.49
Postinfarction myocardial scarring in mice: molecular MR imaging with use of a collagen-targeting contrast agent. Radiology (2008) 1.48
Molecular MR imaging of liver fibrosis: a feasibility study using rat and mouse models. J Hepatol (2012) 1.45
Magnetic nanoparticles: surface effects and properties related to biomedicine applications. Int J Mol Sci (2013) 1.37
MR angiography with blood pool contrast agents. Eur Radiol (2007) 1.28
Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics (2012) 1.24
Molecular MRI of intracranial thrombus in a rat ischemic stroke model. Stroke (2010) 1.24
Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag (2008) 1.21
Perfusion MRI: the five most frequently asked technical questions. AJR Am J Roentgenol (2013) 1.21
DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res (2009) 1.15
Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.12
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med (2009) 1.11
Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr (2010) 1.10
Intra-individual randomised comparison of gadobutrol 1.0 M versus gadobenate dimeglumine 0.5 M in patients scheduled for preoperative breast MRI. Eur Radiol (2012) 1.10
Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol (2009) 1.08
Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging (2012) 1.08
Colocalization of gadolinium-diethylene triamine pentaacetic acid with high-molecular-weight molecules after intracerebral convection-enhanced delivery in humans. Neurosurgery (2011) 1.08
Physicochemical characterization, and relaxometry studies of micro-graphite oxide, graphene nanoplatelets, and nanoribbons. PLoS One (2012) 1.08
T1 relaxivity of core-encapsulated gadolinium liposomal contrast agents--effect of liposome size and internal gadolinium concentration. Acad Radiol (2008) 1.04
Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol (2011) 1.04
Quantitative assessment of macromolecular concentration during direct infusion into an agarose hydrogel phantom using contrast-enhanced MRI. Magn Reson Imaging (2008) 1.04
Fe3O4@organic@Au: core-shell nanocomposites with high saturation magnetisation as magnetoplasmonic MRI contrast agents. Chem Commun (Camb) (2010) 1.02
Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol (2010) 1.01
Dynamic contrast-enhanced magnetic resonance imaging for characterising nasopharyngeal carcinoma: comparison of semiquantitative and quantitative parameters and correlation with tumour stage. Eur Radiol (2013) 1.01
Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities. Magn Reson Imaging (2010) 1.01
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Gd(DOTAla): a single amino acid Gd-complex as a modular tool for high relaxivity MR contrast agent development. J Am Chem Soc (2012) 1.00
Physicochemical characterization of a novel graphene-based magnetic resonance imaging contrast agent. Int J Nanomedicine (2013) 1.00
Surface functionalization of magnetic iron oxide nanoparticles for MRI applications - effect of anchoring group and ligand exchange protocol. Contrast Media Mol Imaging (2010) 0.99
Comparison of three physiologically-based pharmacokinetic models for the prediction of contrast agent distribution measured by dynamic MR imaging. J Magn Reson Imaging (2008) 0.99
Magnetic resonance imaging of hypoxic injury to the murine placenta. Am J Physiol Regul Integr Comp Physiol (2009) 0.99
Optimized high-resolution contrast-enhanced hepatobiliary imaging at 3 tesla: a cross-over comparison of gadobenate dimeglumine and gadoxetic acid. J Magn Reson Imaging (2011) 0.98
Gold-Speckled Multimodal Nanoparticles for Noninvasive Bioimaging. Chem Mater (2008) 0.95
Magnetic resonance and fluorescence imaging of doxorubicin-loaded nanoparticles using a novel in vivo model. Nanomedicine (2010) 0.95
Practical dynamic contrast enhanced MRI in small animal models of cancer: data acquisition, data analysis, and interpretation. Pharmaceutics (2012) 0.94
Pharmacokinetic mapping for lesion classification in dynamic breast MRI. J Magn Reson Imaging (2010) 0.93
Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. Eur Heart J Cardiovasc Imaging (2016) 0.93
Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer. Bioconjug Chem (2012) 0.93
Heteroditopic binding of magnetic resonance contrast agents for increased relaxivity. Angew Chem Int Ed Engl (2011) 0.93
3.0-T whole-heart coronary magnetic resonance angiography: comparison of gadobenate dimeglumine and gadofosveset trisodium. Int J Cardiovasc Imaging (2013) 0.92
Assessment of renal function with dynamic contrast-enhanced MR imaging. Magn Reson Imaging Clin N Am (2008) 0.92
In vitro Gd-DTPA relaxometry studies in oxygenated venous human blood and aqueous solution at 3 and 7 T. Contrast Media Mol Imaging (2014) 0.91
Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging. Contrast Media Mol Imaging (2013) 0.91
High resolution navigated three-dimensional T₁-weighted hepatobiliary MRI using gadoxetic acid optimized for 1.5 Tesla. J Magn Reson Imaging (2012) 0.91
Accelerated stem cell labeling with ferucarbotran and protamine. Eur Radiol (2009) 0.90
Multimodality and nanoparticles in medical imaging. Dalton Trans (2011) 0.89
Using dynamic contrast-enhanced MRI to quantitatively characterize maternal vascular organization in the primate placenta. Magn Reson Med (2014) 0.89
In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor model. Neuro Oncol (2010) 0.89
Consensus report from the 7th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol (2015) 0.88
Integration of ultra-high field MRI and histology for connectome based research of brain disorders. Front Neuroanat (2013) 0.88
In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson (2014) 0.88
Nanoscale assembly of amine functionalized colloidal iron oxide. J Magn Magn Mater (2009) 0.88
Comparison of maximum signal intensity of contrast agent on t1-weighted images using spin echo, fast spin echo and inversion recovery sequences. Iran J Radiol (2012) 0.88
Thoracic and abdominal MRA with gadofosveset: influence of injection rate on vessel signal and image quality. Eur Radiol (2009) 0.88
Potential of hybrid ¹⁸F-fluorocholine PET/MRI for prostate cancer imaging. Eur J Nucl Med Mol Imaging (2014) 0.88
Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells. Int J Nanomedicine (2012) 0.87
Preoperative dynamic contrast-enhanced MRI correlates with molecular markers of hypoxia and vascularity in specific areas of intratumoral microenvironment and is predictive of patient outcome. Neuro Oncol (2013) 0.87
A comparison between gadofosveset trisodium and gadobenate dimeglumine for steady state MRA of the thoracic vasculature. Biomed Res Int (2014) 0.87
Combined magnetic resonance imaging of deep venous thrombosis and pulmonary arteries after a single injection of a blood pool contrast agent. Eur Radiol (2010) 0.87
The magnetic susceptibility effect of gadolinium-based contrast agents on PRFS-based MR thermometry during thermal interventions. J Ther Ultrasound (2013) 0.86
High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review. Eur Radiol (2010) 0.86
Use of cardiac output to improve measurement of input function in quantitative dynamic contrast-enhanced MRI. J Magn Reson Imaging (2009) 0.86
MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles. Int J Nanomedicine (2014) 0.86
A myelin-specific contrast agent for magnetic resonance imaging of myelination. J Am Chem Soc (2011) 0.86
First-pass contrast-enhanced renal MRA at 7 Tesla: initial results. Eur Radiol (2012) 0.86
A polymeric fastener can easily functionalize liposome surfaces with gadolinium for enhanced magnetic resonance imaging. ACS Nano (2013) 0.86
High resolution ultra high field magnetic resonance imaging of glioma microvascularity and hypoxia using ultra-small particles of iron oxide. Invest Radiol (2009) 0.86
Assessing tumor cytoarchitecture using multiecho DSC-MRI derived measures of the transverse relaxivity at tracer equilibrium (TRATE). Magn Reson Med (2014) 0.86
Dynamic contrast-enhanced MRI assessment of hyperemic fractional microvascular blood plasma volume in peripheral arterial disease: initial findings. PLoS One (2012) 0.85
High-resolution motion compensated MRA in patients with congenital heart disease using extracellular contrast agent at 3 Tesla. J Cardiovasc Magn Reson (2012) 0.85
Human brain tumor imaging with a protein-binding MR contrast agent: initial experience. Eur Radiol (2009) 0.85
A responsive particulate MRI contrast agent for copper(I): a cautionary tale. Dalton Trans (2012) 0.85
Quantitative contrast-enhanced first-pass cardiac perfusion MRI at 3 tesla with accurate arterial input function and myocardial wall enhancement. J Magn Reson Imaging (2011) 0.85
Preferential macrophage recruitment and polarization in LPS-induced animal model for COPD: noninvasive tracking using MRI. PLoS One (2014) 0.85
A model-constrained Monte Carlo method for blind arterial input function estimation in dynamic contrast-enhanced MRI: II. In vivo results. Phys Med Biol (2010) 0.85
Accelerated dual-contrast first-pass perfusion MRI of the mouse heart: development and application to diet-induced obese mice. Magn Reson Med (2014) 0.85
Dobutamine stress cardiovascular magnetic resonance at 3 Tesla. J Cardiovasc Magn Reson (2008) 0.85
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future Perspectives. Adv Ther (2016) 0.84
Liver-specific agents for contrast-enhanced MRI: role in oncological imaging. Cancer Imaging (2013) 0.84
Multivariate modelling of prostate cancer combining magnetic resonance derived T2, diffusion, dynamic contrast-enhanced and spectroscopic parameters. Eur Radiol (2015) 0.84
Structure-relaxivity relationships of serum albumin targeted MRI probes based on a single amino acid Gd complex. J Med Chem (2013) 0.84
Synthesis, Characterization, In Vitro Phantom Imaging, and Cytotoxicity of A Novel Graphene-Based Multimodal Magnetic Resonance Imaging - X-Ray Computed Tomography Contrast Agent. J Mater Chem B Mater Biol Med (2014) 0.84
PEG coating reduces NMR relaxivity of Mn(0.5)Zn(0.5)Gd(0.02)Fe(1.98)O4 hyperthermia nanoparticles. J Magn Reson Imaging (2011) 0.84
Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med (2009) 0.84
Human whole-blood (1)H2O longitudinal relaxation with normal and high-relaxivity contrast reagents: influence of trans-cell-membrane water exchange. Magn Reson Med (2013) 0.84
A pilot study using dynamic contrast enhanced-MRI as a response biomarker of the radioprotective effect of memantine in patients receiving whole brain radiotherapy. Oncotarget (2016) 0.84
Studying the effect of particle size and coating type on the blood kinetics of superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2012) 0.84
Gadolinium Chelate Contrast Material in Pregnancy: Fetal Biodistribution in the Nonhuman Primate. Radiology (2015) 0.84
Endocardial and epicardial myocardial perfusion determined by semi-quantitative and quantitative myocardial perfusion magnetic resonance. Int J Cardiovasc Imaging (2011) 0.83
MR angiography of collateral arteries in a hind limb ischemia model: comparison between blood pool agent Gadomer and small contrast agent Gd-DTPA. PLoS One (2011) 0.83
A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol (2008) 2.40
VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology (2004) 2.14
Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol (2008) 1.85
Lipid-rich atherosclerotic plaques detected by gadofluorine-enhanced in vivo magnetic resonance imaging. Circulation (2004) 1.57
Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol (2008) 1.55
Time-resolved contrast-enhanced three-dimensional magnetic resonance angiography of the chest: combination of parallel imaging with view sharing (TREAT). Invest Radiol (2005) 1.18
Magnetic resonance imaging of atherosclerosis by targeting extracellular matrix deposition with Gadofluorine M. Contrast Media Mol Imaging (2007) 1.14
Detection of atherosclerotic plaque with Gadofluorine-enhanced magnetic resonance imaging. Circulation (2003) 1.08
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging (2008) 1.05
Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol (2002) 1.02
Preliminary investigation on rodent-ectoparasite associations in the highlands of Tigray, Northern Ethiopia: implications for potential zoonoses. Integr Zool (2011) 0.98
Gadofluorine m uptake in stem cells as a new magnetic resonance imaging tracking method: an in vitro and in vivo study. Invest Radiol (2006) 0.96
Vascular enhancement in early dynamic liver MR imaging in an animal model: comparison of two injection regimen and two different doses Gd-EOB-DTPA (gadoxetic acid) with standard Gd-DTPA. Invest Radiol (2009) 0.95
Early MR lymphography with gadofluorine M in rabbits. Radiology (2004) 0.93
Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability. Circ Cardiovasc Imaging (2009) 0.91
Adaptability of large carnivores to changing anthropogenic food sources: diet change of spotted hyena (Crocuta crocuta) during Christian fasting period in northern Ethiopia. J Anim Ecol (2012) 0.88
The potential of contrast-enhanced magnetic resonance imaging for predicting left ventricular remodeling. J Magn Reson Imaging (2002) 0.86
Assessment of myocardial viability using standard extracellular and necrosis specific MR contrast media. Acad Radiol (2002) 0.86
Whole-body MR angiography using a novel 32-receiving-channel MR system with surface coil technology: first clinical experience. J Magn Reson Imaging (2005) 0.85
Comparative studies on the efficacy of MRI contrast agents in MRA. Acad Radiol (2002) 0.83
Imaging-therapy computed tomography with quasi-monochromatic X-rays. Eur J Radiol (2008) 0.83
MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent. Contrast Media Mol Imaging (2006) 0.82
Contrast-enhanced MR angiography of the run-off vasculature: intraindividual comparison of gadobenate dimeglumine with gadopentetate dimeglumine. J Magn Reson Imaging (2003) 0.81
Object properties and cognitive load in the formation of associative memory during precision lifting. Behav Brain Res (2008) 0.80
Contrast-enhanced MR imaging of postoperative scars and VX2 carcinoma in rabbits: comparison of macromolecular contrast agent and gadopentetate dimeglumine. Radiology (2003) 0.79
Gadofluorine-enhanced magnetic resonance imaging of carotid atherosclerosis in Yucatan miniswine. Invest Radiol (2006) 0.79
Effects of injection rate and dose on image quality in time-resolved magnetic resonance angiography (MRA) by using 1.0M contrast agents. Eur Radiol (2006) 0.79
Gadolinium-ethoxybenzyl-diethylenetriamine-pentaacetic acid interaction with clinical drugs in rats. Invest Radiol (2002) 0.78
The chromosome 15q14 locus for bipolar disorder and schizophrenia: is C15orf53 a major candidate gene? J Psychiatr Res (2012) 0.77
Dynamic contrast-enhanced MR imaging of VX2 carcinomas after X-irradiation in rabbits: comparison of gadopentetate dimeglumine and a macromolecular contrast agent. Invest Radiol (2003) 0.77
New contrast media designed for x-ray energy subtraction imaging in digital mammography. Invest Radiol (2003) 0.76
CT angiography with gadolinium-based contrast media. Acad Radiol (2006) 0.76
Community Resource Uses and Ethiopian Wolf Conservation in Mount Abune Yosef. Environ Manage (2015) 0.75
Peripheral vessels: MR angiography with dedicated phased-array coil with large-field-of-view adapter feasibility study. Radiology (2003) 0.75
Qualitative and quantitative detection of human pathogenic Yersinia enterocolitica in different food matrices at retail level in Bavaria. Foodborne Pathog Dis (2010) 0.75
Dynamic enhancement features of gadophrin-2 on magnetic resonance imaging: an experimental model of VX2 carcinoma and bacterial abscess in rabbit thigh. Invest Radiol (2002) 0.75
Reversible immobilization of free-ranging African lions (Panthera leo) with medetomidine-tiletamine-zolazepam and atipamezole. J Wildl Dis (2006) 0.75